Summary & Overview
HCPCS J3400: Triflupromazine HCl Injection, Up to 20 mg
HCPCS Level II code J3400 denotes an injectable dose of triflupromazine hydrochloride (up to 20 mg). This code is used to bill for the medication product itself when administered in an outpatient or office-based setting and matters nationally because it standardizes reporting and reimbursement for this specific injectable antipsychotic/antiemetic preparation. Clear identification of the drug product supports pharmacy management, billing accuracy, and utilization tracking across payers. Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what J3400 represents clinically and operationally, typical sites of service where this injectable is administered, and the payer landscape relevant to billing. The publication outlines common billing modifiers associated with medication services and notes when input data are unavailable. It also provides guidance on the kinds of benchmarks and policy issues readers should expect in a fuller analysis—such as payer coverage variations, coding compliance, and documentation considerations—while remaining focused on national policy and billing practice rather than state-level specifics.
Billing Code Overview
HCPCS Level II code J3400 describes an injection of triflupromazine hydrochloride, up to 20 mg. The service involves administration of the antipsychotic/antiemetic medication in a single injectable dose formulation.
Service Type: Medication administration (injectable drug)
Typical Site of Service: Outpatient clinic, physician office, or facility-based outpatient infusion/medication administration area
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with a history of severe psychotic agitation presents to the emergency department after becoming acutely combative and noncompliant with oral antipsychotic therapy. After behavioral de-escalation attempts fail and the patient poses a safety risk to self and staff, the psychiatric and emergency teams decide that an intramuscular antipsychotic injection is required for rapid control of symptoms. The ordered medication is triflupromazine hydrochloride, administered as a single intramuscular injection up to 20 mg (J3400).
The clinical workflow includes: triage and rapid psychiatric assessment, documentation of indications and informed consent (or documented emergency justification if the patient lacks capacity), baseline vitals and fall risk assessment, nursing preparation of medication and syringe, intramuscular administration (typically in the deltoid or ventrogluteal site), observation for sedation, extrapyramidal symptoms, hypotension, and anticholinergic effects, and documentation of medication lot, dose, route, site, and patient response. Subsequent care may include monitoring in an observation unit or psychiatric admission if symptoms persist or safety concerns remain.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to administer and manage the injection is substantially greater than usual (rare for a single injection; document justification). |